Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Latest News on ALLR

Jan 15, 2025, 10:00 AM EST - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Jan 12, 2025, 10:00 AM EST - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Jan 8, 2025, 10:00 AM EST - 9 days ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 12 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 10:00 AM EST - 15 days ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Dec 30, 2024, 2:00 PM EST - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Dec 6, 2024, 5:38 PM EST - 6 weeks ago

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion

Nov 18, 2024, 8:00 AM EST - 2 months ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 11, 2024, 3:45 PM EST - 2 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 11, 2024, 11:15 AM EST - 2 months ago

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Nov 10, 2024, 11:50 AM EST - 2 months ago

The Schall Law Firm Urges Shareholders In Allarity Therapeutics, Inc. To Join A Securities Fraud Case

Nov 9, 2024, 12:30 PM EST - 2 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Nov 8, 2024, 7:00 PM EST - 2 months ago

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 8, 2024, 11:00 AM EST - 2 months ago

The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Nov 8, 2024, 9:45 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 7, 2024, 11:00 AM EST - 2 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Nov 6, 2024, 11:00 AM EST - 2 months ago

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

Nov 5, 2024, 11:00 AM EST - 2 months ago

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Nov 4, 2024, 11:00 AM EST - 2 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 2 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 2 months ago

The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud

Oct 28, 2024, 11:29 PM EDT - 2 months ago

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.

Oct 27, 2024, 11:00 AM EDT - 2 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 24, 2024, 11:00 AM EDT - 3 months ago

The Schall Law Firm Encourages Shareholders To Join A Securities Fraud Case Against Allarity Therapeutics, Inc.

Oct 22, 2024, 8:00 AM EDT - 3 months ago

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Oct 17, 2024, 11:00 AM EDT - 3 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm

Oct 10, 2024, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Oct 8, 2024, 8:00 PM EDT - 3 months ago

Allarity Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Assist The Schall Law Firm

Oct 6, 2024, 6:45 PM EDT - 3 months ago

Allarity Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 3, 2024, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Oct 1, 2024, 6:00 PM EDT - 3 months ago

The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Sep 28, 2024, 8:00 PM EDT - 3 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Assist The Schall Law Firm

Sep 27, 2024, 6:30 PM EDT - 4 months ago

The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Sep 25, 2024, 7:30 PM EDT - 4 months ago

The Schall Law Firm Invites Shareholders To Take Part In A Securities Fraud Case Against Allarity Therapeutics, Inc.

$Allarity Therapeutics Inc Is Being Sued For Securities Related Infractions And Affected Investors Are Urged To Contact The Schall Law Firm$

Sep 22, 2024, 7:00 PM EDT - 4 months ago

Allarity Therapeutics Inc Is Being Sued For Securities Related Infractions And Affected Investors Are Urged To Contact The Schall Law Firm

Sep 21, 2024, 6:00 PM EDT - 4 months ago

The Schall Law Firm Invites Stockholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Sep 20, 2024, 7:00 PM EDT - 4 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Regulations And The Schall Law Firm Urges Investors To Reach Out

Sep 18, 2024, 7:30 PM EDT - 4 months ago

Allarity Therapeutics Inc May Have Defrauded The Public And The Schall Law Firm Seeks Investor Participation In A Case

Sep 17, 2024, 6:00 PM EDT - 4 months ago

Stockholders With Losses In Allarity Therapeutics, Inc. Are Urged To Help The Schall Law Firm With A Lawsuit For Securities Law Violations

Sep 17, 2024, 5:04 PM EDT - 4 months ago

Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 16, 2024, 9:00 PM EDT - 4 months ago

Allarity Therapeutics Inc May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In A Case

Sep 16, 2024, 1:59 PM EDT - 4 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. (ALLR)

Sep 13, 2024, 8:45 AM EDT - 4 months ago

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 11, 2024, 8:00 AM EDT - 4 months ago

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Aug 23, 2024, 8:15 AM EDT - 5 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws

Market Cap	4.57M
Revenue (ttm)	0.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.10

Volume	502,300
Avg Vol	1,175,362
Day's Range	N/A - N/A
Shares Out	4.43M
Stochastic %K	14%
Beta	0.21
Analysts	Hold
Price Target	$6,993.00